CD80 and adenocarcinoma: Subgroup analysis restricted to patients with adenocarcinoma or those that did not have a complete response to CRT yielded similar results with the notable exception being enrichment of HLA-DR/CD80+/CD86+ expression in patients without a history of relapse (Supplemental Table 2).